GGHC
FLGT icon

Gilder Gagnon Howe & Co’s Fulgent Genetics FLGT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,851
Closed -$42K – 293
2017
Q1 		$42K Sell
3,851
-4,483
-54% -$53K ﹤0.01% 266
2016
Q4 		$96K Hold
8,334
– – ﹤0.01% 234
2016
Q3 		$77K Buy
+8,334
New +$76.7K ﹤0.01% 245

Other funds holding FLGT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
SC
Scholtz & Company Stamford, Connecticut $195M AUM 12.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Gilder Gagnon Howe & Co's FLGT Position: Q2 2017 in Review

Gilder Gagnon Howe & Co sold out of Fulgent Genetics (FLGT) in Q2 2017, closing a stake of 3,851 shares — an estimated $42K sold.

Gilder Gagnon Howe & Co first reported a position in FLGT in Q3 2016 and held it in 3 quarters. The position peaked at $96K in Q4 2016. 22 funds tracked by Wall St. Rank hold FLGT as of Q2 2017.

  • Gilder Gagnon Howe & Co reported no remaining Fulgent Genetics position as of Q2 2017 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 3,851 Fulgent Genetics shares in Q2 2017, an estimated $42K.
  • Gilder Gagnon Howe & Co first reported a position in Fulgent Genetics in Q3 2016 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Fulgent Genetics position peaked at $96K in Q4 2016.
  • 22 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2017, filed 1 Aug 2017.